News: Cholecystectomy risk greater for oral vs. transdermal HT

Article

Postmenopausal women using hormone therapy are at higher risk of gallbaldder disease if they use oral rather than transdermal drugs.

Postmenopausal women using hormone therapy (HT) are at higher risk of gallbladder disease if they use oral rather than transdermal drugs, according to study findings published July 10 in BMJ Online First.

Bette Liu, PhD, and colleagues at the University of Oxford in Oxford, UK, analyzed data from the Million Women Study of 1,001,391 postmenopausal women with a mean age of 56 years, of whom 19,889 were admitted to the hospital with gallbladder disease and 17,190 underwent cholecystectomy.

Overall, current users of HT were 1.64 times more likely than women who had never used it to have gallbladder disease, the investigators found. However, for those who used transdermal medication, the risk was only 1.17 times, versus 1.74 times for those on oral therapy. Thus, transdermal HT increased the risk of gallbladder disease by 1.3%, whereas oral therapy increases it by 2%, they note. However, transdermal HT is more costly and can cause local skin reactions, the report indicates. Equine estrogens carried a slightly greater risk than estradiol among women taking oral HT. The risk of gallbladder disease declined after HT treatment ceased, the researchers report.

Liu B, Beral V, Balkwill A, et al. Gallbladder disease and use of transdermal versus oral hormone replacement therapy in postmenopausal women: prospective cohort study. BMJ. 2008;337:a386. doi:10.1136/bmj.a386.

Recent Videos
The significance of the Supreme Court upholding mifepristone access | Image Credit: unchealth.org
One year out: Fezolinetant displays patient satisfaction for managing hot flashes | Image Credit: sutterhealth.org
Addressing maternal health inequities: Insights from CDC's Wanda Barfield | Image Credit: cdc.gov
Addressing racial and ethnic disparities in brachial plexus birth Injury | Image Credit: shrinerschildrens.org
Innovations in prenatal care: Insights from ACOG 2024 | Image Credit:  uofmhealth.org.
Unlocking therapeutic strategies for menopausal cognitive decline | Image Credit: uclahealth.org.
Navigating menopause care: Expert insights from ACOG 2024 | Image Credit: mayo.edu.
raanan meyer, md
© 2024 MJH Life Sciences

All rights reserved.